Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma.
Cancer Treat Rev
; 129: 102788, 2024 Sep.
Article
in En
| MEDLINE
| ID: mdl-38908229
ABSTRACT
In patients with resected non-metastatic melanoma, the liquid biopsy for the assessment of molecular residual disease (MRD) by circulating tumour DNA (ctDNA) represents a promising tool to stratify the risk and to monitor tumour evolution. However, its validation requires the demonstration of analytical validity, clinical validity and utility. Indeed, the development of sensitive and specific assays can optimize prognostication and eventually help clinicians to modulate adjuvant treatments, in order to improve clinical outcomes. Data about ctDNA-guided prognosis stratification is emerging, but clinical trials assessing ctDNA-guided therapeutic decisions are still ongoing. This review aims to depict the role of ctDNA-based MRD assessment in patients with non-metastatic melanoma and to provide a roadmap to face challenges for its introduction into clinical practice.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasm, Residual
/
Circulating Tumor DNA
/
Melanoma
Limits:
Humans
Language:
En
Journal:
Cancer Treat Rev
Year:
2024
Document type:
Article
Affiliation country:
Italy